Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13706126 | 0.93 | HSD17B1 (0.38) | CYP11B1HSD17B1HSD17B2PTGS2KDM4E | |
| SCHEMBL13706285 | 0.90 | CYP11B1 (0.41) | CYP11B1HSD17B1HSD17B2PTGS2KDM4E | |
| SCHEMBL13706202 | 0.89 | PTGS2 (0.34) | CYP11B1HSD17B1HSD17B2PTGS2KDM4E | |
| SCHEMBL13520278 | 0.86 | PTGS2 (0.41) | HSD17B1HSD17B2PTGS2KDM4EMEN1 | |
| SCHEMBL13408823 | 0.82 | HPGD (0.34) | CYP11B1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL13408873 | 0.81 | GPR84 (0.38) | CYP11B1KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL13706271 | 0.79 | ESR1 (0.35) | PTGS2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL13408727 | 0.79 | ALDH1A1 (0.31) | CYP11B1ALDH1A1HPGD | |
| SCHEMBL13706270 | 0.77 | KDM4E (0.34) | PTGS2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL13408699 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090230852-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-09-17 | — | — | US | disclosed |
| US-20090230852-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090230852-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OXER1, L1CAM, RPL41 | CYP11B1 675/4885HSD17B1 1885/4885HSD17B2 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.